Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

J&J Says Its 'Mix-and-Match' COVID-19 Booster With Pfizer Vaccine Shows Increase in Antibody, T-Cell Responses

12/06/2021 | 04:03am EST


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
01/27JOHNSON & JOHNSON : to Participate in Citi's 2022 Virtual Healthcare Conference
PU
01/27Johnson & Johnson to Participate in Citi's 2022 Virtual Healthcare Conference
PR
01/27Health Care Outperform Amid Fading Thursday Markets
MT
01/27Health Care Stocks Still Outperforming Amid Fading Thursday Markets
MT
01/27Galapagos Names Former Johnson & Johnson Executive Paul Stoffels CEO; Shares Soar
MT
01/27MeiraGTx Gets $30 Million Milestone Payment from Janssen Pharmaceuticals for Retinitis ..
MT
01/27MeiraGTx Gets $30 Million Milestone Payment From Janssen Pharmaceuticals
DJ
01/27JOHNSON & JOHNSON : Marks More Than 2 Billion Doses of Medicine Donated to Date to Help Co..
PU
01/27DA Davidson Lifts Johnson & Johnson's Price Target to $196 From $188, Citing 'Increased..
MT
01/26Galapagos Appoints Former Johnson & Johnson Exec to Succeed Retiring CEO
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 304 M - -
Net income 2021 22 542 M - -
Net cash 2021 815 M - -
P/E ratio 2021 20,4x
Yield 2021 2,42%
Capitalization 452 B 452 B -
EV / Sales 2021 4,79x
EV / Sales 2022 4,41x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 171,79 $
Average target price 183,56 $
Spread / Average Target 6,85%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Alex Gorsky Executive Chairman
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON0.42%452 254
ROCHE HOLDING AG-6.24%308 691
PFIZER, INC.-7.99%304 947
ABBVIE INC.1.86%243 826
ELI LILLY AND COMPANY-11.27%222 206
NOVO NORDISK A/S-13.07%218 259